
Join to view full profile
71 Us Route 1 Ste JScarborough, ME 04074
Phone+1 207-396-6433
Fax+1 207-396-6436
Dr. Babirak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1989
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1983 - 1986
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1983
Certifications & Licensure
NH State Medical License 1998 - Present
ME State Medical License 1997 - 2027
PA State Medical License 1992 - 1998
TX State Medical License 1991 - 1992
WA State Medical License 1986 - 1991
MN State Medical License 1984 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2013
Publications & Presentations
PubMed
- 2 citationsTirzepatide Therapy in a Patient with Type 2 Diabetes Mellitus, Chylomicronemia, and Heterozygosity for Lipoprotein Lipase Deficiency.Stephan Paul Babirak
AACE Clinical Case Reports. 2023-05-30 - 2 citationsA retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients.Anne C. Goldberg, Richard L. Dunbar, Linda C. Hemphill, Stephan P. Babirak, Gerald Wilson
Journal of Clinical Lipidology. 2020-08-18 - 146 citationsAlirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak, Marc-Andre Cornier, P. Barton Duell
European Heart Journal. 2016-12-21
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: